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We report striking differences in the substrate specificities of two human SR proteins, SF2/ASF and SC35,
in constitutive splicing. b-Globin pre-mRNA (exons 1 and 2) is spliced indiscriminately with either SR protein.
Human immunodeficiency virus tat pre-mRNA (exons 2 and 3) and immunoglobulin m-chain (IgM) pre-mRNA
(exons C3 and C4) are preferentially spliced with SF2/ASF and SC35, respectively. Using in vitro splicing with
mutated or chimeric derivatives of the tat and IgM pre-mRNAs, we defined specific combinations of segments
in the downstream exons, which mediate either positive or negative effects to confer SR protein specificity. A
series of recombinant chimeric proteins consisting of domains of SF2/ASF and SC35 in various combinations
was used to localize trans-acting domains responsible for substrate specificity. The RS domains of SF2/ASF and
SC35 can be exchanged without effect on substrate specificity. The RNA recognition motifs (RRMs) of SF2/ASF
are active only in the context of a two-RRM structure, and RRM2 has a dominant role in substrate specificity.
In contrast, the single RRM of SC35 can function alone, but its substrate specificity can be influenced by the
presence of an additional RRM. The RRMs behave as modules that, when present in different combinations,
can have positive, neutral, or negative effects on splicing, depending upon the specific substrate. We conclude
that SR protein-specific recognition of specific positive and negative pre-mRNA exonic elements via one or
more RRMs is a crucial determinant of the substrate specificity of SR proteins in constitutive splicing.
Pre-mRNA splicing is an essential step in the expression of
eukaryotic genes (see review chapters in references 17 and 20).
Introns are excised with a high degree of precision in two
successive transesterification reactions, despite the enormous
variability in intron number, size, and sequence in higher eu-
karyotic genes. The critical sequences involved in the transes-
terification reactions, at the 59 splice site, the branch site, and
the 39 splice site, are relatively short and only weakly con-
served. Many silent or cryptic splice site signals are present in
both exons and introns, but they are normally ignored in the
presence of the authentic signals. On the other hand, a number
of pre-mRNAs show flexibility in the choice of alternative
splice sites, often in response to tissue-specific, physiologically,
or developmentally regulated states. Alternative splicing is a
common strategy for the regulation of cellular and viral gene
expression.
Pre-mRNA splicing takes place within a large complex, the
spliceosome, which includes the small nuclear ribonucleopro-
tein particles (snRNPs) U1, U2, U4/U6, and U5 and a large
number of non-snRNP splicing factors. Biochemical character-
ization of the spliceosome, together with genetic studies in
budding yeast, predicts that over 50 proteins are essential for
constitutive splicing. Considerable effort has been devoted to
dissecting the cis elements and trans-acting factors involved in
the complex splicing reaction, but little is known about the
molecular mechanisms responsible for accuracy and specificity.
The members of the SR protein family are well-studied
non-snRNP protein factors required for general pre-mRNA
splicing (reviewed in references 4, 10, and 22). A prototype of
the family, SF2/ASF, was originally purified by biochemical
complementation of splicing-deficient cytosolic S100 extract
from HeLa cells. This assay has been commonly used as a
functional criterion to show the requirement of SF2/ASF or
other SR proteins for constitutive pre-mRNA splicing. An-
other characteristic property of SR proteins is the concentra-
tion-dependent regulation of splice site selection in alterna-
tively spliced pre-mRNAs. SR proteins also share a distinctive
domain structure, which consists of one or two copies of an
RNA recognition motif (RRM), followed by a characteristic
C-terminal arginine/serine-rich (RS) domain. Nine authentic
human SR proteins have been identified to date, and these
belong to two subgroups, based on domain structure. The
members of one subgroup, which comprises SF2/ASF, SRp30c,
SRp40, SRp55, and SRp75, have two RRMs, of which the
second one is somewhat atypical and includes a distinctive
heptapeptide signature. The members of the other subgroup,
which includes SC35, SRp20, 9G8, and p54, have only a single,
N-terminal RRM. All of these SR proteins have been shown to
complement the S100 extract for splicing in vitro. Therefore,
SR proteins appear to have similar, and in some cases redun-
dant, biochemical functions in general splicing, at least in vitro.
In contrast to the apparently interchangeable properties of
different SR proteins in constitutive splicing in vitro, distinct
effects of these proteins in alternative and enhancer-dependent
splicing have been reported. For example, individual SR pro-
teins promote the use of different alternative 59 splice sites with
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certain pre-mRNAs, both in vitro and in vivo (5, 31, 45–47).
Likewise, certain exonic splicing enhancers (ESEs) interact
functionally and sequence specifically with distinct subsets of
SR proteins (12, 28, 36, 40). High-affinity RNA-binding sites
for several SR proteins were identified by iterative in vitro
binding selection (SELEX) (13, 32, 37, 38). Recently, a selec-
tion procedure based on in vitro splicing was employed to
derive consensus ESEs specific for SF2/ASF, SRp40, and
SRp55 (21). SF2/ASF and SC35 are prototypical SR proteins
representative of the two subgroups, and they have distinct
functional properties in some assays. For example, SC35 can
restore splicing in 9G8-depleted nuclear extract but SF2/ASF
cannot (7). Moreover, SF2/ASF and SC35 have antagonistic
effects on alternative splicing of chicken b-tropomyosin pre-
mRNA (11). Genetic studies in Drosophila melanogaster dem-
onstrated that SRp55/B52 is essential for development; how-
ever, it does not appear to be required for splicing of all
pre-mRNAs, suggesting that it has specific pre-mRNA sub-
strates in vivo (27, 29). Recently, SF2/ASF was shown to be
essential for cell viability by targeted gene disruption in a
chicken B-cell line; the lethality could be rescued by expression
of cDNAs encoding human SF2/ASF, but not SC35 or SRp40,
again showing that individual SR proteins have at least some
unique functions (41).
Early studies showed that splicing of a human immunodefi-
ciency virus type 1 (HIV-1) tat/rev minigene transcript is highly
SF2/ASF dependent (18), and this dependence is manifested at
an early step of spliceosome assembly, corresponding to the
formation of an SR protein commitment complex (9). Subse-
quently, it was shown that RRM2 of SF2/ASF, but not RRM1
or the RS domain, plays a crucial role in formation of a specific
commitment complex (8). In the present study, the different
substrate specificities of two SR proteins, SF2/ASF and SC35,
are demonstrated with three representative pre-mRNAs,
b-globin, HIV-1 tat, and immunoglobulin m chain (IgM). The
roles of specific elements on the pre-mRNAs and of individual
domains of SF2/ASF and SC35 in determining substrate spec-
ificity in constitutive splicing are reported.
MATERIALS AND METHODS
Plasmid constructions. The wild-type minigene pre-mRNAs (Fig. 1) were
transcribed from previously described linearized plasmids. b-Globin pre-mRNA
(exon 1, 158 nucleotides [nt]; intron 1, 130 nt; exon 2, 209 nt) was transcribed
from pSP64-HbD6 (19); tat pre-mRNA (tat/rev coding exon 2, 270 nt; intron with
an internal deletion, 163 nt; coding exon 3, 101 nt) was transcribed from pSP64-
HIV-1/tat23 (18); and IgM pre-mRNA (constant exon C3, 154 nt; intron, 107 nt;
constant exon C4, 119 nt) was transcribed from pmC3-C4 (43). The exon swap
(Fig. 2), exon segment deletion (Fig. 3 and 5), and exon segment replacement
(Fig. 4 and 6) derivatives of these tat and IgM minigenes were constructed by one
or more rounds of overlap-extension PCR with appropriate primers. The result-
ing amplification products were cleaved with HindIII and EcoRI and subcloned
into the corresponding sites of the pCRII vector (Invitrogen). The RNA se-
quences of the Ta, Tb, and Tc segments from the tat pre-mRNA and of the Ca,
Cb, and Cc segments from the IgM pre-mRNA are shown below (Fig. 3 and 5).
To delete the previously reported exonic splicing silencer (ESS) region of the tat
construct (Fig. 4) (1, 34), pSP64-HIV-1/tat23 DNA was amplified by PCR with
an upstream SP6 promoter primer and a downstream primer containing the
desired deletion. The amplified product was cleaved with HindIII and BamHI
and subcloned into the corresponding sites of the pSP73 vector (Promega). The
resulting plasmid, pSP73-tatDESS, has a 20-bp deletion of the sequence, GAT
CCATTCGATTAGTGAAC, in the downstream exon 3. All new plasmid con-
structs were verified by sequencing. To generate templates for runoff in vitro
transcription, pSP64-HbD6, pSP64-HIV-1/tat23, pSP73-tatDESS, pCRII-CaTbTc,
and pCRII-CaCbTc were linearized with BamHI. pmC3-C4 and all other pCRII-
derivative plasmids were linearized with HindIII and EcoRI, respectively.
In vitro splicing assays. 32P-labeled pre-mRNA substrates were prepared by
runoff in vitro transcription with SP6 or T7 (only for the pSP73-tatDESS tem-
plate) RNA polymerase as described elsewhere (23). HeLa cell S100 extract and
chimeric SF2/ASF and SC35 glutathione S-transferase-tagged recombinant pro-
teins expressed in baculovirus were prepared as described elsewhere (8, 24).
Purified recombinant, nontagged SF2/ASF and SC35 proteins expressed in bac-
ulovirus were a generous gift from K. Lynch and T. Maniatis. In vitro splicing
complementation reactions were carried out in 25 ml with 9 ml of S100 extract, 10
pmol (0.4 mM final concentration) of a wild-type or chimeric recombinant pro-
tein, and 20 fmol of 32P-labeled pre-mRNA substrate, followed by incubation at
30°C for 1.5 to 4 h as described elsewhere (23). RNA products were analyzed by
electrophoresis on a 5.5% polyacrylamide–7 M urea gel followed by autoradiog-
raphy with an intensifying screen at 270°C.
RESULTS
SF2/ASF and SC35 have distinct pre-mRNA substrate spec-
ificities. To investigate the substrate specificity of SR proteins,
transcripts from various minigene constructs including d-crys-
tallin, IgM, HIV-1 tat, and Drosophila ftz, were tested for splic-
ing in vitro. Using HeLa cell S100 extract, in which SR proteins
FIG. 1. In vitro splicing of three representative pre-mRNAs in S100 extract
complemented with SF2/ASF or SC35. The structures of the b-globin, tat, and
IgM minigene pre-mRNAs (see Materials and Methods) are shown schemati-
cally at the top. The positions of the spliced mRNAs are indicated by arrows. The
asterisk indicates a cleavage product unrelated to splicing (18). The splicing
products were previously characterized in detail (18, 30, 43). pBR322/HpaII
DNA size markers are shown (lanes M).
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are limiting for splicing, we assayed the activity of individual
recombinant SR proteins, including SF2/ASF, SC35, SRp30c,
SRp40, and SRp55 (data not shown). In each of these mini-
gene transcripts, only one pair of authentic splice sites is
present, and hence the assays measure constitutive splicing.
We focused on the substrates and SR proteins that exhibited
the most striking differences in specificity, namely, the tat and
IgM pre-mRNAs spliced in the presence of SF2/ASF and SC35
(Fig. 1). The control b-globin pre-mRNA (G1-G2) gave com-
parable levels of splicing with either SR protein (lanes 1 to 3),
as expected from previous studies. In contrast, the HIV tat
pre-mRNA (T2-T3) spliced when the S100 extract was com-
plemented with SF2/ASF but not when it was complemented
with SC35 (lanes 4 to 6). Conversely, the IgM pre-mRNA
(C3-C4) spliced in the presence of SC35 but not that of SF2/
ASF (lanes 7 to 9).
The downstream exons are responsible for substrate speci-
ficity. As an initial approach to mapping segments of each
pre-mRNA that are responsible for substrate specificity, we
first constructed two hybrid pre-mRNAs, in which the up-
stream or downstream half of b-globin pre-mRNA (G1-G2)
was replaced by the corresponding segment from the IgM
pre-mRNA (C3-C4), with the fusion point located in the mid-
dle of each intron. The hybrid G1-C4 pre-mRNA showed SC35
specificity, as did the parent IgM pre-mRNA, whereas the
C3-G2 hybrid pre-mRNA was spliced with either SF2/ASF or
SC35, similar to the parent b-globin pre-mRNA (data not
shown). To determine whether an SC35-responsive element is
localized exclusively within the IgM C4 exon or within the 39
portion of the preceding intron, downstream exon swapping
constructs were made (Fig. 2). When just the downstream T3
exon of the tat pre-mRNA was replaced with the IgM C4 exon,
FIG. 2. In vitro splicing of hybrid tat and IgM pre-mRNAs with swapped downstream exons. The structures of the control wild-type minigene pre-mRNAs (tat and
IgM) and swap pre-mRNAs (T2-C4 and C3-T3) are shown schematically at the top. The positions of the spliced mRNAs are indicated by arrows. DNA size markers
(lanes M) are as described for Fig. 1.
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the SR protein specificity switched completely from SF2/ASF
to SC35 (lanes 1 to 6). With the reciprocal construct, in which
the downstream C4 exon of the IgM pre-mRNA was replaced
with the tat T3 exon, a full specificity switch from SC35 to
SF2/ASF was observed (lanes 7 to 12). We conclude that spe-
cific SF2/ASF- and SC35-responsive elements are present in
the T3 and C4 downstream exons, respectively.
Mapping of tat pre-mRNA downstream exon elements re-
sponsible for SF2/ASF specificity. To further map the SF2/
ASF-responsive element in the T3 exon of the tat pre-mRNA,
a series of mutants was constructed. Since there is a highly
purine-rich sequence in the middle of the T3 exon and purine-
rich elements frequently function as ESEs (reviewed in refer-
ence 4), we divided the T3 exon into three similarly sized
segments, designated Ta, Tb (purine rich), and Tc. Pre-mRNAs
in which the T3 exon was replaced by each of these segments
alone or in combination were generated and spliced in vitro
(Fig. 3). The three segments mediated very different SR pro-
tein specificities in splicing. The Ta and Tb segments individ-
ually promoted splicing activity with either SF2/ASF or SC35,
whereas the Tc fragment alone was essentially inactive (lanes 4
to 12). Splicing was still observed when the purine-rich Tb
segment was deleted (TaTc), indicating that the purine-rich
segment is not an essential enhancer element in the T3 exon
(lanes 13 to 15). Interestingly, only one combination of two
segments, TbTc, resulted in SF2/ASF-specific splicing, as seen
in the wild-type construct (lanes 1 to 3 and 19 to 21), whereas
the TaTb and TaTc combinations behaved similarly to Ta
alone (lanes 4 to 6 and 13 to 18). With the TbTc substrate,
splicing activity in the presence of SF2/ASF was stronger than
that with the Tb substrate, and splicing activity with SC35 was
completely repressed. Therefore, the Tc fragment, which is
inactive by itself, plays an SC35-specific negative role that
results in SF2/ASF-specific splicing.
To confirm that the specific negative effect of the Tc segment
is due to specific sequences and not, for example, to exon
length, we replaced this segment with a fragment from the 39
end of the IgM C4 exon (Fig. 4). The resulting pre-mRNA,
TaTbCc, regained splicing activity with SC35 and retained ac-
tivity with SF2/ASF (lanes 1 to 6). An ESS was previously
identified in this exon of the tat pre-mRNA, as assayed in vivo
and by in vitro splicing in nuclear extract (1, 34). Within the Tc
FIG. 3. In vitro splicing of tat pre-mRNA derivatives with downstream exon deletions. The structure of the wild-type (wt) tat minigene pre-mRNA, with the T3 exon
divided into three segments, Ta, Tb, and Tc, is shown schematically at the top. The RNA sequence of each segment is shown at the bottom. Previously identified ESE
and ESS elements are underlined (1, 33, 34). The positions of the spliced mRNAs are indicated by arrows; the open arrowhead indicates the expected position in the
case of an mRNA that is at the limit of detection. DNA size markers (lane M) are as described for Fig. 1 (sizes in nucleotides).
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segment (Fig. 3), the mapped ESS sequence, AGAUCCAUU
CGAUUAGUGAA, has been shown to comprise two func-
tional core sequences, AGAUCC and UUAG (33). We there-
fore deleted most of the above 20-nt sequence from the T3
exon and found that splicing activity with SC35 was restored
(Fig. 4, lanes 3 and 9). We conclude that the previously iden-
tified ESS acts by repressing the activity of SC35 but has no
effect on the activity of SF2/ASF (lanes 2 and 8).
Mapping of IgM pre-mRNA downstream exon elements re-
sponsible for SC35 specificity. A similar analysis was per-
formed with the IgM C4 exon, which was arbitrarily divided
into three segments of similar lengths, Ca, Cb, and Cc. Six
constructs with individual segments or combinations thereof in
place of the intact C4 exon were generated and spliced in the
presence of SC35 or SF2/ASF (Fig. 5). In contrast to the above
results with the tat T3 exon, only one of the single-segment
substrates, Cb, was spliced, and this was the case with either
SF2/ASF or SC35 (lanes 4 to 12). Splicing with the Ca sub-
strate was reproducibly below detection. The correct selectivity
for SC35 required two adjacent segments, Ca and Cb, such that
the CaCb substrate spliced much more efficiently in the pres-
ence of SC35 than in the presence of SF2/ASF, similar to the
wild type (lanes 13 to 15). Comparison of the CaCb substrate
with the Ca and Cb substrates suggests that the Ca segment has
repressive activity toward SF2/ASF, although it is also possible
that the distance between the Cb segment and the 39 splice site
differentially affects recognition by SF2/ASF and by SC35
(lanes 4 to 9 and 13 to 15). The other two-segment substrates,
CaCc and CbCc, gave little to no splicing (lanes 16 to 21).
Thus, the Cc segment, which by itself was inactive, inhibited
the activity of the Cb segment (lanes 7 to 12 and 19 to 21).
However, this effect was context dependent, since the Cc ele-
ment was neutral in a heterologous context (Fig. 4, lanes 4 to
6). Two short purine-rich tracts are present within the Cb
(GAGGGAG) and Cc (GUGAAGGG) segments, but disrup-
tion of either purine-rich sequence by mutagenesis had no
effect on splicing efficiency or on SC35 specificity, compared to
the wild-type pre-mRNA (data not shown).
The properties of the Ca and CaCb segments were further
tested in a heterologous context, i.e., the tat pre-mRNA. In-
troduction of the Ca segment in place of the corresponding Ta
segment in exon T3 resulted in a reduction in splicing effi-
ciency, although SR protein specificity was retained (Fig. 6,
lanes 2 and 5). This result confirms that the Ca segment has a
repressive effect with SF2/ASF. When the tat TaTb portion of
the exon was replaced by the corresponding IgM CaCb frag-
ment, a complete switch in SR protein specificity was observed
(lanes 1 to 3 and 7 to 9). Thus, the CaCb region of exon C4 is
a bipartite element that mediates SC35-specific splicing in ei-
ther a homologous or a heterologous pre-mRNA context. We
conclude that the Cb segment includes a cis-acting element(s)
for general splicing activity, whereas the Ca segment is neces-
sary, although not sufficient, for SC35 specificity.
Domains of SF2/ASF and SC35 responsible for substrate
specificity. To determine which of the modular domains of
SF2/ASF and SC35 mediates substrate specificity by recogni-
tion of the above elements, we used a collection of recombi-
nant chimeric proteins that consist of domains from these two
SR proteins in different combinations (Fig. 7). We previously
used these chimeric proteins to show synergy between the two
RRMs of SF2/ASF, but not its RS domain, in mediating for-
mation of a specific SR protein commitment complex with the
tat pre-mRNA (8). In the present study, we have systematically
analyzed the role of the individual domains of SF2/ASF and
SC35 in substrate specificity during constitutive splicing, by
using complementation of SR protein-deficient S100 extract
and three representative substrates, b-globin, tat, and IgM
pre-mRNAs (Fig. 7A).
Efficient splicing of b-globin pre-mRNA was obtained by
complementation with any of the chimeric proteins with a
three-domain structure (Fig. 7A, lanes 2 to 8). This observation
serves as a useful control for the proper folding and functional
integrity of these chimeric proteins. In the case of the tat
pre-mRNA, splicing was observed only with the chimeric pro-
teins possessing the atypical RRM2 of SF2/ASF (lanes 12 and
15), but efficient activity comparable to that of wild-type SF2/
ASF was seen only with the chimera that includes both RRM1
and RRM2 (lanes 10 and 14). Thus, RRM2 of SF2/ASF plays
a key role in tat splicing specificity and it synergizes with the
otherwise neutral RRM1, resulting in much higher splicing
efficiency. The source of RS domain, either from SF2/ASF or
SC35, had no significant influence on SF2/ASF splicing speci-
FIG. 4. In vitro splicing of tat pre-mRNA derivatives with replacement or
internal deletion of exon segment Tc. The structures of the pre-mRNA deriva-
tives are shown schematically at the top. The deleted ESS element (Fig. 3) is
indicated by a horizontal bar, and the black box shows the Cc segment of the IgM
C4 exon (Fig. 5) replacing the Tc segment. The positions of the spliced mRNAs
are indicated by arrows. wt, wild type.
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ficity. However, an RS domain is necessary for splicing activity,
since deletion of the RS domain abolished the activity of the
proteins in the S100 complementation assay (data not shown).
The domain requirements for IgM pre-mRNA splicing were
very different from those observed for tat pre-mRNA splicing.
We found that the chimeric proteins that include the RRM of
SC35 in conjunction with RRM1 of SF2/ASF, but not with
RRM2, were as active as wild-type SC35 (lanes 19, 21, and 24).
However, inclusion of SF2/ASF RRM2 completely abolished
IgM splicing and activated tat splicing (lanes 20, 22, and 23).
Thus, in the three-domain chimeras, the SC35 RRM confers
substrate specificity only when combined with RRM1 of SF2/
ASF. As with the tat pre-mRNA, the source of RS domain had
no effect on splicing specificity. These data are summarized in
Fig. 7B. Taken together, these results demonstrate that the
RRMs, rather than the RS domain, define the substrate spec-
ificity of SF2/ASF and SC35.
To define the role of individual RRMs, we also analyzed
chimeric proteins with a two-domain structure (Fig. 7B). Chi-
meric proteins with a single RRM derived from SF2/ASF,
RRM1 or RRM2, were essentially inactive, whereas the single
RRM of SC35 joined to the RS domain of SF2/ASF (chimeric
protein i) was active and had the same specificity as wild-type
SC35 (Fig. 7B and data not shown), again confirming the
crucial role of the SC35 RRM for the substrate specificity of
SC35. These observations indicate that RRM1 or RRM2 from
SF2/ASF cannot function as a single RRM in conjunction with
an RS domain, in contrast to the RRM from SC35, which can,
as it does in wild-type SC35.
DISCUSSION
Coordinate effects of downstream exon segments mediate
SR protein-specific splicing. Using in vitro splicing with dele-
tion and chimeric derivatives of tat and IgM minigene tran-
scripts, we defined specific segments in the downstream exons
that act in a coordinated manner to determine SR protein-
specific splicing. SF2/ASF-specific splicing, as seen with wild-
type tat pre-mRNA, was observed exclusively with the TbTc
substrate. The Tb and Tc segments act in concert to confer SR
protein specificity, since splicing activity in the presence of
SF2/ASF is stronger than that with the Tb segment alone,
FIG. 5. In vitro splicing of IgM pre-mRNA derivatives with downstream exon deletions. The structure of the wild-type (wt) IgM minigene pre-mRNA, with the C4
exon divided into three segments, Ca, Cb, and Cc, is shown schematically at the top. The RNA sequence of each segment is shown at the bottom. The positions of the
spliced mRNAs are indicated by arrows; the open arrowheads indicate the expected positions in the cases of mRNAs that are at or below the limit of detection. The
identity of the aberrant processing product in lane 11 has not been determined. DNA size markers (lane M) are as described for Fig. 1 (sizes in nucleotides).
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whereas splicing in the presence of SC35 is repressed. In the
case of the IgM pre-mRNA, only two kinds of deleted sub-
strates were spliced at significant levels. The Cb substrate was
spliced indiscriminately with either SF2/ASF or SC35, whereas
the CaCb pre-mRNA displayed SC35-specific splicing, similar
to the wild-type IgM pre-mRNA. Therefore, the Ca and Cb
segments also act in concert to achieve SR protein specificity.
The Tb segment of tat pre-mRNA is highly purine rich,
except for two uridines (Fig. 3), and indeed, in vivo and in vitro
splicing studies previously revealed that a longer region includ-
ing this segment functions as an ESE (1, 34). However, we
found that a substrate containing the Ta segment alone as the
downstream exon spliced more efficiently with SF2/ASF than
did a substrate containing the purine-rich Tb segment alone.
Therefore, in this case the purine-rich segment is not the ESE,
at least with SF2/ASF. Indeed, not all purine-rich sequences
function as ESEs, and conversely, not all ESEs are purine rich
(21, 35, 38, 39). An SF2/ASF-specific splicing enhancer ele-
ment consensus, (C/G)(A/G)(C/G)A(C/G)GA, was recently
identified by functional SELEX and comprises sequences that
are not exclusively purine rich (21). Analysis of the tat T3 exon
with an SF2/ASF motif scoring matrix (21) showed a higher
density of high-score matches to the 7-nt consensus in the Ta
segment than in the Tb segment (data not shown; see Fig. 3 for
the sequences). In addition, replacement of the original tat
ESE with an ESE from Rous sarcoma virus (RSV) causes a
dramatic increase of splicing efficiency in vivo (34); the RSV
ESE sequence has a better match to the above 7-nt consensus
than the exclusively purine-rich tat ESE (data not shown). In
the IgM pre-mRNA, only one high-score motif match to the
SF2/ASF consensus was found in the Cb segment (data not
shown; see Fig. 5 for the sequences), which is consistent with
splicing activity being found exclusively with the Cb and CaCb
substrates. The CaCb segment is necessary and sufficient for
SC35-specific splicing, since the heterologous tat pre-mRNA
behaved like the IgM pre-mRNA upon insertion of this seg-
ment.
Interestingly, both the Tc and the Ca segments have negative
effects, i.e., they are silent by themselves but they can prevent
SC35- and SF2/ASF-specific splicing, respectively, in combina-
tion with other segments. The Ca segment includes sequences
that prevent splicing in the presence of SF2/ASF, and this
effect was verified in a heterologous pre-mRNA. The Tc seg-
ment in the tat T3 exon includes a previously identified ESS (1,
33, 34). The role of this ESS element was tested by deletion,
and we found that splicing with SF2/ASF was not affected,
whereas splicing with SC35 was largely restored by deletion of
the 20-nt ESE fragment. Therefore, the repressive effect of this
ESS may be SC35 specific, and this is consistent with the fact
that only partial inhibition of splicing by the ESS was observed
in vivo and in vitro (33, 34). Thus, other SR proteins, e.g.,
SF2/ASF in this case, may be involved in recognition of this
exon. However, the function of the ESS is sensitive to the
sequence context. We did not observe a strong SC35-repressive
effect of the Tc segment when it was joined to the Ta segment,
i.e., the Ta and TaTc substrates showed similar SR protein
specificities. Furthermore, we failed to observe SC35-specific
splicing repression with the CaCbTc pre-mRNA. In this case,
the positive effect of the CaCb segment for SC35-specific splic-
ing is dominant over the negative effect of the Tc segment,
which includes the ESS. The context dependence of the neg-
ative effect by the Tc segment does not appear to be a function
of the distance to the upstream 39 splice site, since this distance
is very similar in the TaTbTc and CaCbTc substrates, but
repression is seen only with TaTbTc (wild type). Our observa-
tion is consistent with, and extends, previous in vivo splicing
experiments, which showed that this ESS does not repress
splicing in the context of pre-mRNAs containing an ESE from
the fibronectin gene or a b-globin intron (34). Likewise, it was
recently shown that this ESS is less active in the context of an
optimal or strong 39 splice site (33).
The existence of a cellular inhibitory factor(s) that binds to
the ESS elements of the tat pre-mRNA exon 2 and exon 3,
which have similar sequences, was suggested by splicing assays
performed in the presence of competitor RNA (1, 33). We
observed that complementation reactions with SF2/ASF and
SC35 together resulted in decreased splicing efficiency with the
tat pre-mRNA; this negative effect was not observed with other
pre-mRNAs (data not shown). In fact, with the b-globin and
TaTbTcDESS pre-mRNAs, additive effects of SF2/ASF and
SC35 were observed, suggesting the presence of two or more
ESEs and in agreement with the previous observation that
splicing efficiency increases linearly with the number of ESEs
present in an exon (14). SELEX experiments identified se-
quences that are bound with high affinity by SC35 lacking the
RS domain but which do not function as ESEs (38). Interest-
ingly, the sequence AUUCGAUUA, which has a 7- of 9-nt
match to one of the SELEX winners identified in that study,
GUUCGAGUA, is present in the tat exon 3 ESS (Fig. 3).
FIG. 6. In vitro splicing of tat pre-mRNA derivatives with replacements of
downstream exon segments. The structures of the pre-mRNAs are shown sche-
matically at the top. The positions of the spliced mRNAs are indicated by arrows.
wt, wild type.
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Together, the above observations suggest that SC35 itself
may bind directly to the tat ESS and behave in this context as
an inhibitor, rather than an activator. This suggestion is con-
sistent with recent data showing that the ESS inhibits splicing
by blocking the formation of a functional spliceosome at an
early step (33). In the published experiments with competitor
RNAs, SC35 may be titrated out, so that it can no longer bind
to the functional SC35 binding site on the pre-mRNA. This is
reminiscent of the sequestration of SR proteins by binding to
viral RNAs possessing high-affinity binding sites for SR pro-
teins (15). When the ESS is present in cis, there are several
potential reasons why SC35 may be inhibitory. First, binding
may be too tight to be compatible with function; second, the
geometry of binding may be inappropriate; third, SC35 binding
may prevent binding of other required coactivators. Inhibitory
effects of SR proteins, including SF2/ASF and SC35, were
previously reported in adenovirus and RSV src pre-mRNAs,
although in these cases the negative elements are present in
the introns (16, 26). In the chicken b-tropomyosin pre-mRNA,
SC35 also acts as an inhibitor, antagonizing inclusion of an
alternative exon mediated by SF2/ASF, which recognizes an
intronic splicing enhancer (11).
In contrast to our current, as well as previous, in vitro splic-
ing studies (references 9, 18, and 44 and this study), in vivo
depletion of SF2/ASF was recently shown to increase splicing
of tat pre-mRNA from a stably transfected minigene in a
chicken B-lymphocyte cell line (42). There are many possible
explanations for this apparent discrepancy, including the use of
cell-free versus in vivo systems, cell-type-specific differences,
differences in the abundance and ratios of various SR proteins
and other splicing factors, and potential compensatory mech-
anisms that may operate in vivo when the abundance of an SR
protein is manipulated.
Unique properties of the RRMs mediate substrate specific-
ity. The substrate specificity of several chimeric recombinant
SR proteins with various combinations of RRM or RS domains
derived from SF2/ASF or SC35 was determined with three
reference substrates. We demonstrated that the substrate spec-
ificity of these SR proteins is defined by their RRMs, of which
two are present in SF2/ASF and one is present in SC35,
whereas the C-terminal RS domains of these proteins do not
affect the substrate specificity and are interchangeable.
The function of each RRM in constitutive splicing is unique,
and when two RRMs are present, they can markedly influence
each other. Neither RRM1 nor RRM2 from SF2/ASF can
function in constitutive splicing as a single RRM when joined
FIG. 7. (A) In vitro splicing of b-globin, tat, and IgM pre-mRNAs with wild-type or chimeric glutathione S-transferase-tagged SR proteins assembled from different
combinations of SF2/ASF and SC35 domains. See panel B for the designation of each protein. The structures of the pre-mRNAs are shown schematically at the top.
The positions of the spliced mRNAs are indicated by arrows. DNA size markers (lanes M) are as described for Fig. 1. (B) Summary of the splicing activities of the
chimeric SR proteins with each pre-mRNA. The domain structure of each protein is shown schematically, with the designation used in panel A. The relative splicing
complementation activities are indicated (2, no detectable activity; 1/2, trace activity; 1, weak activity; 11, strong activity) and are based on two independent
experiments, one of which is shown in panel A.
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to an RS domain. In contrast, the single RRM from SC35 has
evolved to function in this context, and when joined to a het-
erologous RS domain, it is sufficient to confer SC35 specificity.
RRM1 and RRM2 of SF2/ASF have naturally evolved as part
of a double-RRM structure, and they synergize to give maxi-
mal splicing activity with the substrate specificity of SF2/ASF.
The distinctive RRM2 of SF2/ASF is required for activity with
the tat pre-mRNA, and it abrogates the activity of the SC35
RRM with the IgM pre-mRNA. Therefore, RRM2 can affect
other RRMs positively and negatively. Of the three RRMs
analyzed here, RRM1 of SF2/ASF has the most neutral char-
acter and does not affect the specificity conferred by the SC35
RRM. These data support the idea that each RRM in double-
RRM SR proteins has been fine-tuned during evolution to
function as part of a bipartite RNA-binding domain while
retaining significant modular character. Similar conclusions
have been reached in the case of the SR protein antagonist in
alternative splicing, hnRNP A1 (25).
The RS domains of SF2/ASF and SC35 are interchangeable
in the constitutive in vitro splicing assays with b-globin, IgM,
and tat pre-mRNAs. This observation is consistent with the
recent finding that the RS domain of SF2/ASF can be replaced
by those of three other SR proteins tested, including SC35, to
maintain the viability of a chicken B-lymphocyte cell line (42).
On the other hand, the specific sequences of the RS domains
of each SR protein are highly conserved phylogenetically,
FIG. 7—Continued
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which is strongly indicative of specific roles for each RS do-
main (2). Individual RS domains have been shown to mediate
different subnuclear targeting and nuclear-cytoplasmic shut-
tling properties (5, 6), and these unique functions may be
important at the organismal level or in certain cell types.
Substrate specificity appears to be determined in the early
stages of spliceosome assembly, since the three-domain chi-
meric proteins that include RRM2 from SF2/ASF can form
specific commitment complexes with the tat pre-mRNA, de-
spite the presence of other SR proteins in the nuclear extract
(8). However, in the case of two-domain chimeric proteins
including RRM1 from SF2/ASF, but not those including
RRM2, stable commitment complexes can also form, allowing
splicing of b-globin and IgM pre-mRNAs. In the S100 comple-
mentation assay, however, single-RRM proteins with either of
the SF2/ASF RRMs were inactive. The SR protein commit-
ment assay may be more permissive because of the presence of
endogenous SR proteins, which may interact with the mutant
or chimeric proteins in the preassembled commitment com-
plex.
It is striking that of the six chimeric proteins that had splic-
ing activity in the complementation assay (of nine tested), all of
them displayed substrate specificity patterns that qualitatively
resembled either that of wild-type SF2/ASF or that of SC35.
Thus, although all these proteins were very active with at least
one substrate, none were active with tat or IgM but not b-glo-
bin, active with b-globin but neither tat nor IgM, or active with
all three transcripts. The exclusion of these patterns suggests
that each of the transcripts possesses a distinctive set of rec-
ognition sequences that can be productively recognized in only
a limited number of ways by the RRMs. There is already
considerable evidence that individual SR proteins interact spe-
cifically with ESE elements (12, 21, 28, 36–38, 40). Although
how individual RRMs interact with specific segments of pre-
mRNA, resulting in splicing specificity, is not yet known, the
present results suggest that each RRM interacts directly or
indirectly with specific exon segments, including splicing en-
hancers or silencers.
Modular nature of SR proteins in the context of different
functions. The roles of the structural domains of several SR
proteins were previously studied in other contexts. Unique
roles of the RRMs in alternative splicing regulation were pre-
viously documented in vivo with adenovirus E1A pre-mRNA,
which has three alternative 59 splice sites. In contrast to the
present and to previous results with constitutive splicing activ-
ity (3, 48), deletion of either RRM from SF2/ASF yields pro-
teins that retain activity in alternative 59 splice-site switching,
although different 59 splice sites are selected depending upon
which RRM is deleted (5). The fact that single-RRM proteins
possessing either RRM1 or RRM2 from SF2/ASF function in
alternative splicing but not in constitutive splicing assays sug-
gests that the mechanisms of SR protein involvement in these
two contexts are distinct. It is possible that the more permissive
domain requirements for alternative splicing reflect interac-
tions between the mutant protein and endogenous SR pro-
teins, since the alternative splicing assays are carried out in
vivo or in nuclear extract, i.e., in the presence of multiple,
wild-type SR proteins (3, 5, 31, 48). This would also be con-
sistent with the more permissive domain requirements for SR
protein function in the commitment assay, which is carried out
in nuclear extract as well (8).
The RS domain of SR proteins is essential for an exclusive
nuclear localization although it is not sufficient for subnuclear
targeting in double-RRM SR proteins (5). Some but not all SR
proteins shuttle continuously between the nucleus and the cy-
toplasm, a process for which the RS domain is a critical deter-
minant (6). On the other hand, RS domains are interchange-
able between SR proteins, at least in terms of the viability
requirements of a B cell grown in culture (42). In these previ-
ous studies, as well as in the present study, chimeric proteins
with specific combinations of SR protein domains were shown
to be functional in a variety of assays, underscoring the mod-
ular character of SR proteins and the contribution of individ-
ual domains to different functions.
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